TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37580840

Group type: EXPERIMENTAL
Intervention: Proposed pipeline with novel feature selection strategies
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional pipeline reflecting common radiomics practice
Number of subjects: 101
Study: 37580874

Group type: EXPERIMENTAL
Intervention: Isometric (ISO) task
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Concentric (CON) task
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cycling (BIKE) task
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Last common stages performed in ISO
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Last common stages performed in BIKE
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Task failure
Number of subjects: 38
Study: 37581275

Group type: EXPERIMENTAL
Intervention: Deep Brain Reorienting (DBR)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist (WL) control
Number of subjects: 54
Study: 37581385

Group type: EXPERIMENTAL
Intervention: Plasma Trimethylamine
Number of subjects: 0
Study: 37581388

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study: 37581390

Group type: EXPERIMENTAL
Intervention: Right ventricular (RV) systolic dysfunction
Number of subjects: 90
Study: 37581394

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) in patients with ATTR-CM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study: 37581498

Group type: COMPARATOR
Intervention: Contrast-enhanced mammography (CEM)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Abbreviated breast MRI (ABMRI)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Standard breast MRI
Number of subjects: 246
Study: 37581593

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab with CHOP chemotherapy
Number of subjects: 40
Study: 37581616

Group type: EXPERIMENTAL
Intervention: Binimetinib
Number of subjects: 341

Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (PCC)
Number of subjects: 341
Study: 37581619

Group type: EXPERIMENTAL
Intervention: Gallium-68-labelled DOTATATE
Number of subjects: 22
Study: 37581673

Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (1 g of conjugated estrogen cream, 0.625 mg/g)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Vaginal estrogen
Number of subjects: 206
Study: 37581909

Group type: EXPERIMENTAL
Intervention: Domestic Violence Intervention (DeVI) combining Problem Management Plus counseling and violence prevention component
Number of subjects: 912

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 912
Study: 37581981

Group type: EXPERIMENTAL
Intervention: Midostaurin (50 mg twice daily) plus chemotherapy (idarubicin or daunorubicin) for 21 days
Number of subjects: 301

Group type: COMPARATOR
Intervention: Midostaurin (50 mg twice daily) plus chemotherapy
Number of subjects: 301
Study: 37582084

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (PFT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chest computed tomography (CT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abnormal CT findings (bronchiectasis, reticulation, ground-glass opacities)
Number of subjects: 100
Study: 37582097

Group type: EXPERIMENTAL
Intervention: PNE program + MR program
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Traditional biomedical information + MR program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 37582096

Group type: EXPERIMENTAL
Intervention: Addition of fructose-containing sugars (excess energy from sugars added)
Number of subjects: 5213

Group type: EXPERIMENTAL
Intervention: Fruit and 100% fruit juice (low doses, up to or less than ~10% E)
Number of subjects: 5213

Group type: EXPERIMENTAL
Intervention: Mixed sources (with sugar-sweetened beverages [SSBs]) at high doses (up to 23%)
Number of subjects: 5213

Group type: EXPERIMENTAL
Intervention: Removal of SSBs (up to ~20% E)
Number of subjects: 5213

Group type: COMPARATOR
Intervention: Substitution, subtraction, or ad libitum trials of total fructose-containing sugars
Number of subjects: 5213
Study: 37582154

Group type: EXPERIMENTAL
Intervention: Electromagnetic bronchoscopic and transthoracic navigation
Number of subjects: 0
Study: 37582169

Group type: EXPERIMENTAL
Intervention: State-of-the-art PCI
Number of subjects: 754

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 754
Study: 37582170

Group type: EXPERIMENTAL
Intervention: Tricuspid transcatheter edge-to-edge repair with the TriClip implant
Number of subjects: 85
Study: 37582265

Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 664
Study: 37582274

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37582340

Group type: EXPERIMENTAL
Intervention: Secondary revascularization (SR)
Number of subjects: 869

Group type: COMPARATOR
Intervention: No myocardial revascularization failure (MRF)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Disease progression
Number of subjects: 869
Study: 37582474

Group type: EXPERIMENTAL
Intervention: Manual physical therapy (3 sessions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 120
Study: 37582633

Group type: EXPERIMENTAL
Intervention: Recreational drug use (positive test for recreational drugs)
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Cannabis, cocaine, and MDMA use (assessed separately)
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Multiple drug detection (28% of positive patients)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: No recreational drug use (negative test)
Number of subjects: 1499
Study: 37582719

Group type: EXPERIMENTAL
Intervention: Continuous passive paracentesis for up to 7 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Large-volume paracentesis (LVP) performed intermittently according to clinical practice, maximum duration of 8 hours
Number of subjects: 70
Study: 37582730

Group type: EXPERIMENTAL
Intervention: Coronary catheterization (CC) procedure once
Number of subjects: 136495

Group type: COMPARATOR
Intervention: Coronary catheterization (CC) procedure twice
Number of subjects: 136495

Group type: EXPERIMENTAL
Intervention: Coronary catheterization (CC) procedure
Number of subjects: 136495
Study: 37582736

Group type: EXPERIMENTAL
Intervention: Adaptive goal setting
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Immediate reinforcement
Number of subjects: 512

Group type: COMPARATOR
Intervention: Delayed reinforcement
Number of subjects: 512

Group type: COMPARATOR
Intervention: Static goal setting
Number of subjects: 512
Study: 37582746

Group type: EXPERIMENTAL
Intervention: Peer-led social mobilisation into community-based integrated adolescent and youth friendly HIV and sexual and reproductive health care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of Care (UTT and PrEP) delivered through primary health clinics
Number of subjects: 40
Study: 37582775

Group type: EXPERIMENTAL
Intervention: Gingivitis
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Periodontitis Stage III
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Periodontitis Stage II
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Periodontitis Stage I
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: BMI increase
Number of subjects: 314
Study: 37582945

Group type: EXPERIMENTAL
Intervention: Nivolumab and oligo-fractionated irradiation (22.5 Gy/5 fractions/5 days)
Number of subjects: 40
Study: 37582952

Group type: EXPERIMENTAL
Intervention: Elranatamab (subcutaneous, once weekly after two step-up priming doses)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Elranatamab (biweekly dosing after six cycles for persistent responders)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Elranatamab (overall treatment)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Elranatamab (biweekly dosing)
Number of subjects: 123
Study: 37583261

Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase levels
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Blood viscosity
Number of subjects: 235
Study: 37583267

Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (BGF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 0
Study: 37583434

Group type: EXPERIMENTAL
Intervention: High preoperative blood levels of oxaloacetate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High preoperative blood levels of 2-aminoadipic acid (2-AAA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (patients without dNCR)
Number of subjects: 67
Study: 37583699

Group type: COMPARATOR
Intervention: Multiple sclerosis patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relapsing multiple sclerosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue-Factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-5 discriminating variables for model (1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-5 discriminating variables for model (2)
Number of subjects: 0
Study: 37583881

Group type: EXPERIMENTAL
Intervention: EMA-based phone counseling and instant messaging for smoking cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 37583905

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study: 37583920

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 40
Study: 37584207

Group type: EXPERIMENTAL
Intervention: Dual-therapy sirolimus-eluting and CD34 antibody-coated COMBO stent (DTS)
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Sirolimus-eluting Orsiro stent (SES)
Number of subjects: 3146
Study: 37584233

Group type: EXPERIMENTAL
Intervention: Amulet occluder
Number of subjects: 1878

Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 1878
Study: 37584254

Group type: EXPERIMENTAL
Intervention: RSV 10 mg/AML 5 mg
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: RSV 20 mg/AML 5 mg
Number of subjects: 259

Group type: COMPARATOR
Intervention: ATV 20 mg/AML 5 mg
Number of subjects: 259
Study: 37584273

Group type: EXPERIMENTAL
Intervention: N. gonorrheae/C. trachomatis positive cases
Number of subjects: 605

Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 605
Study: 37584290

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa-Kd)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 61
Study: 37584291

Group type: EXPERIMENTAL
Intervention: Close surveillance instead of upfront hematopoietic stem cell transplantation (HSCT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Close surveillance instead of upfront HSCT
Number of subjects: 7

Group type: COMPARATOR
Intervention: Allogeneic HSCT
Number of subjects: 7
Study: 37584292

Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment for refractory chronic GVHD
Number of subjects: 0
Study: 37584309

Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII)
Number of subjects: 53
Study: 37584344

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 619

Group type: COMPARATOR
Intervention: Standard vaccine
Number of subjects: 619
Study: 37584362

Group type: EXPERIMENTAL
Intervention: Patients developing MINS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Patients without MINS
Number of subjects: 72
Study: 37584365

Group type: EXPERIMENTAL
Intervention: Mitra sampling for pharmacokinetic evaluations
Number of subjects: 0
Study: 37584370

Group type: EXPERIMENTAL
Intervention: LB-100
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: endothall
Number of subjects: 0

Group type: COMPARATOR
Intervention: LB-105 and endothall-D6
Number of subjects: 0
Study: 37584609

Group type: EXPERIMENTAL
Intervention: Active individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin resistance individuals
Number of subjects: 0
Study: 37584841

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) extended-release buprenorphine (BPN) depots (CAM2038)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Sublingual (SL) buprenorphine (BPN)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: SC CAM2038 weekly and monthly
Number of subjects: 252
Study: 37584898

Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate 15 mg administered on day 1 and at months 3, 6, and 9
Number of subjects: 32
Study: 37585220

Group type: EXPERIMENTAL
Intervention: Oropharyngeal swabs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower respiratory tract samples
Number of subjects: 0
Study: 37585243

Group type: EXPERIMENTAL
Intervention: Self-administered web-based dietary recall
Number of subjects: 194

Group type: COMPARATOR
Intervention: Interviewer-administered 24-hour dietary recall
Number of subjects: 194
Study: 37585253

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37585254

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37585260

Group type: EXPERIMENTAL
Intervention: mobile app + volunteer support + TAU (volunteers)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: mobile app + TAU (apps)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TAU only (TAU)
Number of subjects: 40
Study: 37585282

Group type: EXPERIMENTAL
Intervention: Pivot (mobile smoking cessation program)
Number of subjects: 188

Group type: COMPARATOR
Intervention: QuitGuide (control)
Number of subjects: 188
Study: 37585454

Group type: EXPERIMENTAL
Intervention: DME patients (1,502)
Number of subjects: 11005

Group type: COMPARATOR
Intervention: Non-DME controls (5,603)
Number of subjects: 11005
Study: 37585569

Group type: EXPERIMENTAL
Intervention: Two-phased telehealth model for PTSD treatment
Number of subjects: 0
Study: 37585628

Group type: EXPERIMENTAL
Intervention: GNT0003 (gene therapy) - higher dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GNT0003 (gene therapy) - lower dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GNT0003 (gene therapy)
Number of subjects: 5
Study: 37585627

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone (no radiotherapy)
Number of subjects: 500
Study: 37585652

Group type: EXPERIMENTAL
Intervention: Surgery during Lockdown 2
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Surgery during Lockdown 3
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Women patients
Number of subjects: 253

Group type: COMPARATOR
Intervention: All cohorts
Number of subjects: 253
Study: 37585730

Group type: EXPERIMENTAL
Intervention: CT-angiography (CTA) screening for intracranial aneurysms (IAs)
Number of subjects: 500
Study: 37586052

Group type: EXPERIMENTAL
Intervention: Vibegron treatment, dosage and duration not specified
Number of subjects: 0
Study: 37586057

Group type: EXPERIMENTAL
Intervention: Vibegron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 37586317

Group type: EXPERIMENTAL
Intervention: TAEST16001 T cell therapy after dose-reduced lymphodepletion with cyclophosphamide (15 mg/kg/day × 3 days) and fludarabine (20 mg/m2/day)
Number of subjects: 0
Study: 37586350

Group type: EXPERIMENTAL
Intervention: Surgical treatment (n = 40)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medical treatment (n = 26)
Number of subjects: 66
Study: 37586364

Group type: EXPERIMENTAL
Intervention: Nicotinamide adenine dinucleotide (NAD) treatment; specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; specific details not mentioned
Number of subjects: 0
Study: 37586475

Group type: EXPERIMENTAL
Intervention: Mepolizumab (100 mg subcutaneously every 4 weeks for 52 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (every 4 weeks for 52 weeks)
Number of subjects: 0
Study: 37586560

Group type: EXPERIMENTAL
Intervention: Bi-weekly home food delivery from the local food bank
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bi-weekly financial assistance with healthy food access navigation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Traditional CHW services, nutrition educational materials, and provision of basic essential cooking tools
Number of subjects: 160
Study: 37586649

Group type: EXPERIMENTAL
Intervention: Ergonomic infant carrier and instructions on proper use
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 100
Study: 37586823

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 211

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 211
Study: 37586835

Group type: EXPERIMENTAL
Intervention: Descemet's membrane endothelial keratoplasty (DMEK)
Number of subjects: 8998

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PKP)
Number of subjects: 8998

Group type: COMPARATOR
Intervention: Descemet's stripping (automated) endothelial keratoplasties (DSAEKs)
Number of subjects: 8998

Group type: COMPARATOR
Intervention: Deep anterior lamellar keratoplasties (DALKs)
Number of subjects: 8998
Study: 37586845

Group type: EXPERIMENTAL
Intervention: Colchicine treatment 0.5 mg two times per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Colchicine treatment
Number of subjects: 40
Study: 37586862

Group type: EXPERIMENTAL
Intervention: biomodulation protocol (cryobiomodulation, photobiomodulation, electrobiomodulation) administered during the first 6 weeks after surgery
Number of subjects: 146

Group type: COMPARATOR
Intervention: control group (no additional biomodulation protocol)
Number of subjects: 146
Study: 37586869

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (pre-CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Up-front surgery
Number of subjects: 0
Study: 37586882

Group type: EXPERIMENTAL
Intervention: PD-ProS derived from 14 differentially expressed proteins (DEPs) identified through LASSO analysis.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: PD-ProS validated in an independent internal validation cohort of 71 patients with nongenetic PD and 35 HCs.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: PD-ProS using 5 of the 14 DEPs measured in the LCC.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: PD-ProS for distinguishing genetic PD from genetic prodromals.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: PD-ProS predicting cognitive decline in PD.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: PD-ProS predicting motor decline in PD.
Number of subjects: 420
Study: 37586906

Group type: EXPERIMENTAL
Intervention: Intramuscular fat fraction (IMFF) ≥ 15%
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Significant weight loss
Number of subjects: 116
Study: 37587149

Group type: EXPERIMENTAL
Intervention: cetuximab-800CW
Number of subjects: 65
Study: 37587183

Group type: EXPERIMENTAL
Intervention: Amplatzer Piccolo™ Occluder
Number of subjects: 200
Study: 37587184

Group type: EXPERIMENTAL
Intervention: IV caffeine 20 mg/kg followed by up to two daily doses of 5 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IV caffeine 20 mg/kg followed by up to two daily doses of 10 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IV caffeine (both dosages)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Whole-Body Hypothermia for HIE trial
Number of subjects: 17
Study: 37587323

Group type: EXPERIMENTAL
Intervention: HCV cure (DAAs treatment)
Number of subjects: 2740

Group type: COMPARATOR
Intervention: Current or past unhealthy alcohol use
Number of subjects: 2740

Group type: COMPARATOR
Intervention: Living in poverty
Number of subjects: 2740

Group type: COMPARATOR
Intervention: Severe liver fibrosis
Number of subjects: 2740

Group type: COMPARATOR
Intervention: Women
Number of subjects: 2740
Study: 37587489

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention combined with face-to-face sessions and regular telephone contact
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 202
Study: 37587493

Group type: EXPERIMENTAL
Intervention: Guselkumab at Weeks 0, 4, then every 8 weeks (Q8W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study: 37587492

Group type: EXPERIMENTAL
Intervention: Intravenous arginine therapy (200 mg/kg loading dose, max 20 g; followed by 100 mg/kg three times a day, max 10 g)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo (normal saline loading dose followed by normal saline three times a day)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Intravenous arginine therapy
Number of subjects: 360
Study: 37587502

Group type: EXPERIMENTAL
Intervention: FLYSYN (Fc-optimized antibody directed to FLT3/CD135), administered intravenously at different dose levels (0.5 mg/m² in cohort 1-5)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: FLYSYN (Fc-optimized antibody directed to FLT3/CD135)
Number of subjects: 31
Study: 37587516

Group type: EXPERIMENTAL
Intervention: Impaired RV GLS (> -15.4%)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: RV GLS
Number of subjects: 659
Study: 37587517

Group type: EXPERIMENTAL
Intervention: High-touch implementation support (facilitation and tailored technical assistance)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard low-touch implementation support (based on Replicating Effective Programs)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caregivers FIRST participation
Number of subjects: 24
Study: 37587552

Group type: EXPERIMENTAL
Intervention: electronically delivered Cognitive Behavioral Therapy (e-CBT) program
Number of subjects: 100

Group type: COMPARATOR
Intervention: web-based mental health check-in program
Number of subjects: 100
Study: 37587580

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7119

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor
Number of subjects: 7119
Study: 37587591

Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (0.6 mg daily) with ticagrelor or prasugrel
Number of subjects: 200